<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
     xmlns:dc="http://purl.org/dc/elements/1.1/"
     xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
     xmlns:admin="http://webns.net/mvcb/"
     xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
     xmlns:content="http://purl.org/rss/1.0/modules/content/"
     xmlns:media="http://search.yahoo.com/mrss/">
<channel>
<title>My American Doctor &#45; : Lung Cancer</title>
<link>https://myamericandoctor.in/rss/category/Lung-Cancer</link>
<description>My American Doctor &#45; : Lung Cancer</description>
<dc:language>en</dc:language>
<dc:rights>@myamericandoctor.in</dc:rights>

<item>
<title>Osimertinib (Tagrisso): Latest Approval Updates for Early&#45;Stage Lung Cancer — What Patients and Families Need to Know</title>
<link>https://myamericandoctor.in/Osimertinib-Tagrisso-for-Early-Stage-Lung-Cancer</link>
<guid>https://myamericandoctor.in/Osimertinib-Tagrisso-for-Early-Stage-Lung-Cancer</guid>
<description><![CDATA[ Osimertinib (Tagrisso) has become a transformative targeted therapy for EGFR-mutated non-small cell lung cancer. Between 2021 and 2024, the FDA granted landmark approvals covering early-stage post-surgical treatment (ADAURA trial, 2021), unresectable Stage III disease following chemoradiation (LAURA trial, September 2024), and advanced disease in combination with chemotherapy (FLAURA2 trial, February 2024). The 2023 ACS lung cancer screening guidelines now recommend annual low-dose CT scans for adults aged 50–80 with a 20+ pack-year smoking history, regardless of when they quit. Eligibility for osimertinib requires confirmed EGFR mutation testing — making molecular profiling at diagnosis absolutely non-negotiable for every NSCLC patient. ]]></description>
<enclosure url="https://myamericandoctor.in/uploads/images/202602/image_870x580_6997ac141e8a9.jpg" length="114905" type="image/jpeg"/>
<pubDate>Fri, 20 Feb 2026 05:57:00 +0530</pubDate>
<dc:creator>My American Doctor</dc:creator>
<media:keywords>osimertinib lung cancer, Tagrisso EGFR approval, Tagrisso early stage lung cancer, osimertinib FDA approval 2024, EGFR mutation lung cancer treatment, ADAURA trial osimertinib, LAURA trial NSCLC, Tagrisso stage III lung cancer, FLAURA2 osimertinib chemotherapy, EGFR-mutated NSCLC treatment India, targeted therapy lung cancer, osimertinib adjuvant therapy, ACS lung cancer screening guidelines 2023</media:keywords>
</item>

<item>
<title>Non&#45;Small Cell Lung Cancer (NSCLC): What Every Indian Needs to Know Right Now</title>
<link>https://myamericandoctor.in/non-small-cell-lung-cancer</link>
<guid>https://myamericandoctor.in/non-small-cell-lung-cancer</guid>
<description><![CDATA[ Non-Small Cell Lung Cancer is the most common form of lung cancer, accounting for approximately 85% of all cases globally. Its three main subtypes — adenocarcinoma, squamous cell carcinoma, and large cell carcinoma — differ in biology, location, and treatment approach. In India, between 40 and 50% of lung cancer patients are non-smokers, making air pollution, indoor biomass combustion, secondhand smoke, and genetic factors critically important risk factors for the Indian population. Early-stage NSCLC is typically asymptomatic; by the time symptoms are undeniable, the cancer has often advanced. The updated 2023 ACS guideline now recommends annual LDCT screening for current and former smokers aged 50–80 with a 20+ pack-year history, with no quit-year restriction. Comprehensive molecular and biomarker testing before treatment is essential. Modern treatment including targeted therapy, immunotherapy, and surgery offers meaningful hope — but early detection determines the options available. ]]></description>
<enclosure url="https://myamericandoctor.in/uploads/images/202602/image_870x580_69952923a5d1f.jpg" length="145435" type="image/jpeg"/>
<pubDate>Wed, 18 Feb 2026 08:17:45 +0530</pubDate>
<dc:creator>My American Doctor</dc:creator>
<media:keywords>non-small cell lung cancer India, NSCLC symptoms, lung cancer non-smoker India, NSCLC diagnosis and treatment, lung cancer Delhi air pollution, NSCLC overview, adenocarcinoma lung cancer, EGFR mutation lung cancer India, lung cancer screening guidelines ACS 2024, LDCT lung cancer screening, targeted therapy NSCLC, immunotherapy lung cancer, lung cancer signs India, squamous cell lung cancer, lung cancer biomarker testing</media:keywords>
</item>

</channel>
</rss>